The most direct, authoritative, and category-defining domain name in the gene editing industry. Two words the world already knows. One address no one yet owns — until now.
Exact-match domains in high-value B2B sectors carry measurable advantages: higher organic search authority, faster brand recall, and immediate credibility with institutional investors, clinical partners, and regulatory bodies. CrisprPharmaceuticals.com is not adjacent to the category — it is the category, in a single URL.
CRISPR is now a household term. Pharmaceuticals is the industry. Together they form the most precise, most trusted, most investable domain name available in the gene editing space today.
Read the full analysis →Clinical-stage and commercial companies developing Cas9, Cas12, or next-gen nuclease-based medicines for genetic diseases and cancers.
Next-generation editing companies moving beyond DSBs to more precise single-base corrections with superior safety profiles.
LNP, AAV, and novel in vivo delivery platform companies enabling systemic CRISPR deployment in liver, muscle, CNS, and eye.
Major pharmaceutical companies building internal CRISPR capabilities or launching dedicated gene editing business units.
Companies using CRISPR to engineer universal allogeneic CAR-T cells, TCR-T cells, and next-gen solid tumor therapies.
Developers targeting rare monogenic diseases — sickle cell, Huntington's, Duchenne MD, TTR amyloidosis — with curative intent.
The companies that will define the gene editing century are being built right now. The domain that leads the category should belong to one of them.
Begin Acquisition